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Background and purpose of the study: p38α is a member of mitogen-activated protein kinases (MAPK)
considered as a prominent target in development of anti-inflammatory agents. Any abnormality in the
phosphorylation process leads to the different human diseases such as cancer, diabetes and inflammatory diseases.
Several small molecule p38α inhibitors have been developed up to now. In this regard, structural elucidation of p38
inhibitors needs to be done enabling us in rational lead development strategies.
Methods: Various interactions of three potent inhibitors with p38α active site have been evaluated in terms of
binding energies and bond lengths via density function theory and MD simulations.
Results: Our comparative study showed that both ab initio and MD simulation led to the relatively similar results in
pharmacophore discrimination of p38α inhibitors.
Conclusion: The results of the present study may find their usefulness in pharmacophore based modification of
p38α inhibitors.
Keywords: p38α, Anti-inflammatory, Amino acid decomposition analysis, DFT, Molecular dynamicIntroduction
In the process of drug discovery, lead generation is a key
bottleneck. The costly experimental testing of so many
compounds leads to a real challenge in high throughput
screening (HTS) method and makes it critical to perform
virtual screening techniques to reduce the size of chemical
collection richen in active compounds [1]. Computer
based prescreening of chemical databases has found its
key role in lead identification and is known as in silico
drug design. Generally speaking, in silico drug design falls
into four categories that are related to each other depending
on the structural information on targets and their ligand.
These methods are structure-based design, ligand-based
design, combinatorial chemistry-based design and de novo
design [2].
De novo design techniques are used in the case of known
receptor structure and unknown ligand structure. One of
the most efficient and rational methods to afford this
challenge is fragment based drug design [3,4]. In fragment* Correspondence: mirir@sums.ac.ir
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reproduction in any medium, provided the orbased drug design, binding of small molecule fragments
(MW< 300, No. H-donors < 3, No. H-acceptors < 3,
ClogP < 3) [5] to specific domain of active site is evaluated.
Based on the binding energies, best fragments are selected
and bridged together with appropriate linker(s) to generate
new scaffolds. The reverse process, i.e. fragmentation of
ligands to constructing fragments, can be used for
modification of known ligands. By fragmentation, the
chemical diversity of fragment database decreases and the
chance of achievement to new lead compound increases. In
this process, assessment of interaction between fragments
and receptor is the rate limiting step. Estimating the contri-
bution of individual amino acid-ligand interaction energies
in total binding energy, i.e. Amino acid Decomposition
Analysis (ADA) [6-8], would be a very useful trend in
fragment development. ADA is based on receptor
structure and could be applied to different types of
scaffolds. The power of ADA in predicting the effect of
individual residues on ligand-receptor interactions can be
used as supporting information in drug design. In this
regard, estimation of the optimum binding geometry
could assist in choosing the best fragment(s) leading to
the improved ligand potency profiles.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the largest family of signaling proteins, regulates cell life.
More than 500 protein kinases are encoded by the human
genome and it is no surprise that any abnormality in
the phosphorylation process would lead to the different
human diseases such as cancer, diabetes and inflammatory
diseases. Different types of these regulating enzymes are
introduced as therapeutic target. The active site conserva-
tion between protein kinases makes it a real challenge to
design selective agents [9-12]. Therefore evaluation of
structural features of these protein kinases and the role of
fragments to achieve selectivity may be regarded as an
important topic.
p38 belongs to the family of mitogen-activated protein
kinases (MAPK). p38 MAPKs are generally divided to
various isoforms including α, β, γ and δ types [13,14].
p38α and p38β are vital biological targets in inflammatory
pathways [15]. MAP kinase kinase3 and 6 (MKK3, 6) are
activated by inflammatory factors such as IL-1, TNFα and
cell stress [16-18]. MKK3 and 6 are upstream kinases that
phosphorylate the tyrosine and threonine residues in p38α
and hence activate it [19]. The activated p38α stimulates
the IL-1, TNFα and COX-2, enhances the transcription of
inflammatory genes, and also has been found to stabilize
the inflammatory response protein mRNAs [20,21].
Considering the important role in inflammatory pathways,
p38 can be regarded as an attractive target to design
and develop anti-inflammatory agents. Indeed, p38α is a
distinguished target in development of anti-inflammatory
agents. Different classes of p38α inhibitors have been
developed up to now and their pharmacophore were
evaluated in detail [22-27]. In the present contribution,
we used MD simulations and ab initio method to evaluate
pharmacophore model of three potent type Ι p38α inhibi-
tors comprehensively. The results of both MD and ab
initio methods were reported and compared with each
other. Three different inhibitors, diarylimidazole [28],
dihydroquinazolinone [29] and 2-arylpyridazin-3-one [30]
scaffolds were selected for our study (Figure 1). These
inhibitors are direct ATP-binding site inhibitors with
sub-micromolar to nanomolar activity. SB203580 inhibits
p38α and β with almost similar potency. This compound
is ~10 times selective towards p38α/β compared to
p38γ/δ [31].
In the case of SB203580, crystallographic studies
(PDB code 1A9u, resolution: 2.50 Ǻ) demonstrated
that pyridyl nitrogen formed a hydrogen bond with
Met109 (Figure 2). Moreover; 4-fluorophenyl ring oc-
cupied the hydrophobic pocket adjacent to the
Met109. These two types of interactions have been
observed in most of the ATP-binding inhibitors [32].
Nitrogen atom of imidazole ring interacts with Lys53
via hydrogen bond and electrostatic forces. Electro-
static forces are long range interactions between ligandand receptor and have determinant effect on ultimate
ligand-receptor complex stability.
For dihydroquinazolinone (PDB code: 1M7Q, resolution:
2.40 Ǻ) and 2-arylpyridazin-3-one (PDB code: 2I0H,
resolution: 2.00) scaffolds, the same pattern of binding
in the p38α active site have been reported (Figure 2)
[29,30]. Both of these inhibitors have a carbonyl moiety
that interacts with Met109 and Gly110 backbone NH via
hydrogen bonds. 2,4-diflourophenyl and 2-chloro-4-
flouropheny moieties in dihydroquinazolinone and 2-
arylpyridazin-3-one inhibitors occupied the hydrophobic
pocket in the proximity of Met109. Dihydroquinazolinone
scaffold has an additional hydrogen bond with His107 and
2-arylpyridazin-3-one has more hydrophobic interactions
when compared with dihydroquinazolinone.
In this project we used ab initio method and MD
simulations to pharmacophore modeling of these three
potent inhibitors via ADA strategy. B3LYP functional [33]
and BP86 functional [34] together supplemented with
triple-ζ basis set (TZV) [35] were used with the aim of:
– Evaluation of ligand-p38α stability via molecular
dynamic simulations
– ADA through MD simulations and ab initio method
to detect hot spots in p38α active site
– Comparative evaluation of MD and ab initio results
Materials and methods
Preparation of data set
X-ray crystallographic structures of p38α with its cognate
ligands were obtained from Brook Haven Protein databank
(www.rcsb.org). The Swiss PDB Viewer program
(http://www.expasy.org/spdbv) [36] was used to rebuilt
and add missed atoms of Lys15 and Arg173 in 1M7Q and
2I0H PDB structures. The crystallographic holo structures
were used as a starting point for MD simulations. The
force field parameters of ligands were obtained using
PRODRG, an automated topology generation tool web
server [37]. The electrostatic potential (ESP) derived
charges of ligands were all recalculated according to
Breneman and Wiberg [38] by using B3LYP/TZV(2d,2p)
method and were adjusted in topology file.
The evaluated amino acid residues were selected on the
basis of information from schematic 2D representations
of ligand-receptor interactions produced by LIGPLOT
program [39].
In ab initio studies, all amino acids were considered in
their real electrostatic state. Each residue under study was
truncated at the C-terminal and N-terminal. N-terminal
was acetylated and C-terminal was methyl amidated to
mimic the original electron density profile. All conform-
ational and configurational features were the same as the
X-ray structure. Molecular images were produced using
VMD program [40].
Figure 1 Structure of diarylimidazole (SB203580) IC50: 4.8 nM (A), dihydroquinazolinone IC50: 2.6 nM (B) and 2-arylpyridazin-3-one
IC50: 5 nM (C) p38α type Ι inhibitors.
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Molecular dynamics simulations were carried out using
GROMACS 4 package with the standard GROMOS96
force field [41]. In each case, the p38-ligand complex
was solvated in a cubic box with the dimension of 95 ×
95 × 95 (all in Ǻ). Explicit simple point charge model
(SPC216) was used to represent water molecules [42].
Na+ atoms were added to neutralize the total charge of
the systems. Short-range interactions were evaluated using
a twin-rang cutoff with van der Waals and electrostatic
interactions truncated at 12 and 10 Ǻ, respectively.
Particle mesh Ewald (PME) method was used to evaluate
long-range electrostatic interactions. The protein-ligand
complex and waters along with ions were coupled in
a temperature bath at 300K, separately (τT = 0.1 ps).
Berendsen barostat (τp = 1 ps) was used to maintain
pressure in 1.0 atm [43,44]. Linear constraint solver
(LINCS) was applied to constrain all bonds [45].
In the first step, energy minimization was performed
using steepest descent integrator realized in GROMACS
package. After energy minimization, 100 ps NVT and
NPT ensembles were used to equilibrate system. During
NVT and NPT ensembles a harmonic position restrain
(1000 kJ mol-1 nm-1) was applied to all the heavy atoms
of the p38α and ligand. Following equilibration step,
production of MD simulation was conducted for 20 ns
without any constrains. Finally, analysis programs included
in GROMACS package were used to evaluate trajectories.
Ab initio method
All calculations were performed on a structure that
obtained by averaging over last 10 ns of MD simulations.
Heavy atom-hydrogen bonds were optimized by using
heavy atom fixing approximation (constrained optimiza-
tions). Constrained optimization was used to prevent
irrational movement of the side chains. Otherwise theposition of ligand and relevant residue could be changed
drastically. Neese and Bykov evaluated optimization
errors of this type [46]. According to their evaluation,
obtained results are reliable. BP86 functional together in
association with triple-ζ basis set (TZV) was used in
optimization process. Resolution-of-identity (RI) approxi-
mation [47] together with fitting auxiliary basis set TZV/J
[48] was applied for all atoms.
Energy calculations were done using B3LYP (Becke-Lee-
Yang-Parr) functional in association with triple-ζ basis set
(TZV) on optimized structures. For these calculations,
chain-of-spheres (RIJCOSX) approximation [49] was in-
voked. Two set of first polarization functions were applied
on hydrogen and non-hydrogen atoms [TZV(2d,2p)]. To
consider long-range dielectric effect of protein in our
calculation, COSMO model [50] with a dielectric constant
of 4.8 was applied [51]. All calculations were done using
the ORCA quantum chemistry package [52].
Ligand-residue binding energies (ΔEb) were calculated
using the previously introduced equation [53]. Counter-
poise correction [54] was used to take into account basis
set superposition error (BSSE). In the case of SB203580,
Potential Energy Surface (PES) scan were performed in
the direction of hydrogen bond with Met109 in forty
steps considering 0.05Å step sizes. The PES calculations
were performed by the same method and basis set as
mentioned above.
Results and discussion
MD simulations
Crystallographic structure of p38α with its cognate ligands
enabled us to perform MD simulations and evaluate the
role of individual amino acids in total binding energy.
This structure was used as starting conformation for
our simulations. In the first step, we performed a 20 ns
MD simulation to reach a stable trajectory.
Figure 2 2D schematic representation of interactions between SB203580 (A), dihydroquinazolinone (B) and 2-arylpyridazin-3-one (C)
scaffolds and p38α active site generated by LIGPLOT.
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assessment of total energy, temperature and RMSD
(Figures 3 and 4).The Average temperature during 20 ns MD simulation
at 300.0K was found to be 300K (±1.32, 1.34 and 1.33
respectively) for these systems (Figure 3). These results
Figure 3 Total energy and temperature variations during 20 ns MD simulation; SB203580 (A), dihydroquinazolinone (B) and
2-arylpyridazin-3-one (C).
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conservations for the studied systems were desirable.
The RMSDs of ligands in the active site of p38α with
respect to their initial structures were used to evaluate
the stabilities of these three complexes.
In the case of SB203580 (Figure 4A), RMSD rose up to
1.13 Ǻ at the beginning of MD simulations and fluctuated
around this value (± 0.15) for the rest of simulation. This
distribution pattern demonstrated us that ligand achieved
to the equilibrium state just after 1 ns distinguished by the
RMSD profile. For dihydroquinazolinone scaffold (1M7Q),Figure 4 RMSD of ligand atoms; SB203580 (A), dihydroquinazolinoneRMSD increased to 0.71 Ǻ and leveled off to nearly 3 ns
(Figure 4B). At this point of simulation, RMSD rose
up again to 1 Ǻ and leveled off (± 0.13). In the case of
2-arylpyridazin-3-one scaffold, RMSD increased to 0.76 Ǻ
and fluctuated around (± 0.16) over the course of MD
simulation time (Figure 4C). These data showed that
evaluated ligands reached to an equilibrium state after
preliminary fluctuations.
During MD simulations the average of 1.2 H-bond(s)
could be detected between SB203580 and p38α active site
residues (Figure 5A). The variation of donor-acceptor(B) and 2-arylpyridazin-3-one (C).
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the forming and breaking of H-bonds. Over the whole
process, the donor-acceptor distances less than 3.5 Ǻ dem-
onstrated hydrogen bond formation. As can be seen in
Figure 5A, pyridine nitrogen-Met109 NH distance remained
less than 3 Ǻ for the whole simulation time (green).
This fact could convince us in considering a permanent
H-bond between these two moieties. But hydrogen
bond between imidazole nitrogen and quaternary amine
hydrogen of Lys53 was significantly less detectable.
This hydrogen bond was formed and broken frequently
during MD simulations (Figure 5A blue).
In the case of dihydroquinazolinone scaffold, an
average of 1.5 H-bond(s) with p38α active site residues
(Figure 5B) could be detected. Results showed that H-
bond between Met109 NH and ligand O18 atoms
(green) existed during whole MD simulation period.
The distance between His107 O and ligand HN13
atoms remained less than 3.5 Ǻ during MD simulation
(blue). According to obtained results, these two hydro-
gen bonds are permanent during 20 ns MD simula-
tions. The Gly110 NH-ligand O18 distance (red)
fluctuated between 5 ns and 20 ns. However the aver-
aged distance remained higher than 0.35 Ǻ for 98.8%
of the simulation period (Temporary H-bond, Table 1).
2-arylpyridazin-3-one scaffold formed an average of
1.2 H-bond(s) with Met109 and Gly110 during MD
simulation (Figure 5C). In this case, the distance
between Met109 NH and ligand O18 atoms was almost
under 0.35 Ǻ in the whole period (green). But the
distance between Gly110 NH and ligand O18 atoms was
higher than 0.35 Ǻ in 49.5% of simulation period (blue).
These outcomes showed that Met109-ligand and Gly110-
ligand H-bonds were of permanent and temporary types,
respectively.Figure 5 Number and distance of H-bonds between ligands and p38α
2-arylpyridazin-3-one (C).On the basis of results (Table 1), it might be concluded
that hydrogen bond between ligand and Met109 is the
key structural point in binding to the receptor. This
interaction is the common structural feature of all type Ι
p38α inhibitors. More detailed analysis of H-bonds
between p38α active site residues and evaluated ligands
is summarized in Table 1.
After obtaining an equilibrium system, ADA was
carried out as follow: participation of each amino acid
in total binding energy was computed by evaluation of
Lennard-Jones (LJ) and coulombic interaction energies
between each amino acid and ligands via performing
an additional 1 ns MD simulation in each case. The
results of ADA are shown in Figure 6 and Table 2.
Negative energy shifts showed that the residue made
favorable contribution to ligand-receptor interactions.
LIGPLOT program [39] was used to detect residues
that interact with ligand in each case. Based on the
obtained data, same binding pattern to p38α active site
could be detected in all the scaffolds. Interaction energies
with hinge region residues (Met109, Gly110, and Ala111)
are significant and in each case at least, there is one
interaction with these amino acids. Residues constructing
hydrophobic pocket in the proximity of Met109 were
almost involved in interactions with ligand.
In SB203580, Lys53 was found to be the most significant
residue in ligand-receptor interactions (ΔE: -5.77 kcal/mol).
Nitrogen atom of an imidazole ring participated in H-bond
with quaternary amine hydrogen of Lys53. In fact electro-
static forces between these groups made it a favorable
interaction. Lys53 had maximum coulombic and LJ inter-
action energies in these series (−1.64 and −4.13 kcal/mol,
respectively). Electrostatic interactions are important
forces in primary approach of ligand and receptor to each
other. These types of interactions are of long-range typeactive site residues; SB203580 (A), dihydroquinazolinone (B) and
Table 1 Hydrogen bond analysis between evaluated ligands and p38α residues
System Donor Acceptor1 H-bond distance2 (Ǻ) H-bond angle3 (degree) Occupancy (%)
1A9U Met109 NH Ligand N10 2.14 ( ± 0.24) 14.2 ( ± 8.78) 99.8
Lys53 HZ Ligand N18 3.66 ( ± 0.85) 58.5 ( ± 23.7) 39.7
1M7Q Met109 NH Ligand O18 2.06 ( ± 0.32) 14.4 ( ± 11.4) 99.8
Gly110 NH Ligand O18 5.30 ( ± 1.15) 55.1 ( ± 29.0) 11.2
Ligand HN13 His107 O 1.98 ( ± 0.20) 14.4 ( ± 8.10) 100
2I0H Met109 NH Ligand O18 2.09 ( ± 0.28) 23.9 ( ± 14.8) 99.8
Gly110 NH Ligand O18 3.81 ( ± 1.58) 38.2 ( ± 28.5) 50.5
1Atom numbers are according to Figure 2.
2The average H-bond distance with standard deviation in parentheses.
3The average H-bond angle with standard deviation in parentheses.
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stability. According to the obtained results, imidazole ring
(interacting with Lys53) is a very important moiety in
diarylimidazole based p38α inhibitors.
Met109 backbone hydrogen formed a hydrogen bond
with pyridine nitrogen (ΔE: -4.61 kcal/mol). Hydrogen bond
with hinge region residue (Met109) is the key feature of
ATP binding site (type Ι) inhibitors and could be observed
in all type Ι inhibitors. Accumulated negative charge on
pyridine ring of SB203580 formed a favorable interaction
(hydrogen bond and electrostatic forces) with Met109.
Ala51, Leu75, Leu104 and Thr106 contributed to
important hydrophobic contacts in the hydrophobicFigure 6 Contribution of each residue of p38α in binding to SB20358
scaffolds (calculated by MD simulations).pocket (ΔE: -2.76, -0.87, -2.83 and −2.34 kcal/mol,
respectively). These hydrophobic interactions had mini-
mum coulombic interaction energies (Table 2). Due to
the reported pharmacophore models of diverse classes of
p38 MAPK [22], interactions with Met109 and this
hydrophobic pocket are the chemical features designated
for type Ι p38α inhibitors. Tyr35 participated in π-π
stacking interaction with para-methylsulfinyl phenyl ring
of SB203580 (ΔE: -3.59 kcal/mol).
In the case of dihydroquinazolinone scaffold (1M7Q),
His107 (−4.28 kcal/mol), Met109 (−4.24 kcal/mol), Gly110
(−4.72 kcal/mol) and Asp168 (−4.86 kcal/mol) residues
had maximum binding energies. His107, Met109 and0 (A), dihydroquinazolinone (B) and 2-arylpyridazin-3-one (C)
Table 2 LJ and coulombic interaction energies (kcal/mol) between p38α active site residues and evaluated ligands
1A9U 1M7Q 2I0H
Residue Coul LJ Residue Coul LJ Residue Coul LJ
Ala51 −0.23 −2.53 Ala51 −0.39 −3.21 Ala51 −0.05 −1.95
Leu75 0.00 −0.87 Ala111 0.11 −1.79 Ala111 0.08 −2.06
Leu104 −0.48 −2.35 Asp168 −3.56 −1.30 Asp112 −1.61 −3.66
Lys53 −1.64 −4.13 Gly110 −2.09 −2.63 Gly110 −1.31 −2.44
Met109 −2.87 −1.74 His107 −3.56 −0.72 Leu108 −0.32 −3.49
Thr106 0.10 −2.44 Leu167 0.00 −3.15 Leu167 0.01 −5.62
Tyr35 0.11 −3.70 Lys53 0.69 −4.04 Lys53 0.21 −4.11
Met109 −2.23 −2.01 Met109 −0.58 −1.39
Thr106 0.12 −1.85 Thr106 −1.48 −3.37
Tyr35 −1.15 −2.41 Tyr35 −0.07 −7.86
Val30 0.01 −1.06
Val38 0.00 −3.04
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via electrostatic interactions (maximum coulombic inter-
action −3.56 kcal/mol). Lys53 had minimum coulom-
bic interaction energy (0.69 kcal/mol) due to nearness of
Lys53 quaternary amine to positive N42 atom in this
ligand.
2-arylpyridazin-3-one scaffold (2I0H) had maximum
biding energy with Tyr35. Our model indicated that
Isoindoline-1,3-dione ring interacted with Tyr35 via π-π
stacking. This interaction was associated with maximum LJ
interaction energy (−7.86 kcal/mol). Met109 (−1.97 kcal/
mol) and Gly110 (−3.75 kcal/mol) backbone NHs
interacted with ligand O18 atom via H-bond. This lig-
and had more hydrophobic interactions in comparison
with previous ones. LJ and coulombic interaction energies
in each case were summarized in Table 2.
By using ADA we could model the binding mode of
three different p38α inhibitors. Obtained results were in
good agreement with evaluated pharmacophore models
in the literature [22].Ab initio evaluation
In this part we used ab initio method to evaluate contri-
bution of individual amino acid-ligand interaction energies
in total binding energy and compare obtaining results with
MD simulations.
The constrained optimization process was done using
BP86/TZV method on a structure which was obtained by
averaging over last 10 ns MD simulations. All ab initio
studies were done on achieved optimized structure.
Various interaction energies between studied p38α
inhibitors and selected residues in the active site were
obtained independently. The relevant data are shown in
Figure 7.Interactions between imidazole nitrogen and quaternary
amine of Lys53 in SB203580 had the most considerable
interaction energy (−4.66 kcal/mol) (Figure 7A). This
strong interaction occurred as a result of electrostatic
forces between positive nitrogen (cationic Lys53, atomic
partial charge: +0.51) and partially negative imidazole N1
atom (atomic partial charge: -0.62). This ionic dipole
interaction had determinant participation in total ligand-
receptor binding energy.
Another important interaction could be recorded
between Met109 and pyridine nitrogen (−2.30 kcal/mol).
Interestingly, residues participated in hydrophobic inter-
actions exhibited repulsive interaction with evaluated
inhibitor. In the case of Tyr35, the repulsive interaction
may be interpreted on the basis of inappropriate orienta-
tion of ligand para-methylsulfinyl phenyl ring versus Tyr35
phenyl ring. It should be noted, p38α inhibitors lacking this
moiety might not have any significant effect on ligand
potency [28].
Asp168 carboxylic moiety interacts via electrostatic
forces with quaternary amine in dihydroquinazolinone
ligand. This major interaction had prominent binding
energy in this series of residues. Hydrogen bond between
Met109 backbone NH and ligand O18 atom had binding
energy equal to −8.78 kcal/mol. Negative binding energies
could be detected between His107 backbone NH and
HN18 (−6.34 kcal/mol), Gly110 backbone NH and ligand
O18 atom (−4.16 kcal/mol) but like the other ones all
hydrophobic interactions had positive contribution in
binding energy. Proximity of Lys53 and ligand quaternary
amines made this interaction inefficient.
In the case of 2-arylpyridazin-3-one scaffold, Cation-π
interaction could be detected between Lys53 and 4-
flouro-2-methilphenyl moiety. This interaction had
maximum binding energy. Hydrogen binding could be
Figure 7 Contribution of each residue of p38α in binding to SB203580 (A), dihydroquinazolinone (B) and 2-arylpyridazin-3-one
(C) scaffolds (calculated by ab initio).
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and ligand O18 atom (−12.66 and −6.27 kcal/mol,
respectively).
Owing to the important role of hydrogen bond with
Met109 in type Ι inhibitors, we decided to optimize the
geometric position of the involving functional group in
the SB203580 ligand. For this purpose, hydrogen bond
distance between Met109 backbone hydrogen and
pyridyl nitrogen in SB203580 was scanned in the ori-
ginal direction. The maximum interaction energy was
found in the 2.25 Å bond length (data was not shown).
The optimum distance between pyridine nitrogen and
Met109 backbone hydrogen after 20 ns MD simulation
was calculated to be 2.14 Å. These findings interestingly
showed that ab initio method and MD simulations con-
verged to the same results. Moreover, it was demon-
strated that crystallographic structures may not be
appropriate starting points for ab initio calculations in
all cases.
Comparison of the two methods
MD simulations and ab initio methods were used to
calculate the involvement of each amino acid in total
binding energy. The results of applied methods werecompared to reveal the accuracy and efficiency levels.
Our calculations revealed that MD simulations and ab
initio based studies led to the similar trends in estimation
of amino acid-ligand binding energies. In both methods
residues responsible for major interactions in the p38α
active site could be recognized with adaptable level of
reproducibility (Figures 6 and 7).
For p38α active site, ab initio method resulted in more
repulsive hydrophobic and more attractive electrostatic
interactions when compared to MD simulations (Figure 8).
This effect seemed to be probably related to the solvent
effect and also interactions among adjacent residues.
Moreover B3LYP method tended to produce more
polarized wave function in electrostatic interactions [55]
leading to false positive values.
For instance in p38α, Lys53 interacted with Asp168
and this electrostatic interaction decreased the attract-
ive interaction between Lys53 and SB203580 in MD
simulations. But in ab initio study, just the interaction
between Lys53 (truncated at N-terminal and C-terminal)
and ligand was considered. Similar binding patterns for
nearly all residues could be detected while in the case of
charge-assisted interactions (Lys53, Asp168), significant de-
viations were seen (Figure 8). However, relatively similar
Figure 8 Comparative results of MD simulations (green) and ab initio studies (red) in SB203580 (A), dihydroquinazolinone (B) and
2-arylpyridazin-3-one (C) scaffolds.
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Two rationales might be envisaged for this different
trend:
– Solvent effects were attended in MD simulations
while ab initio studies were performed in
vacuum
– In SB203580, Lys53 interacted with partially
negative imidazole sp2 nitrogen atom
– Probable repulsive forces between
dihydroquinazolinone piperazinium and Lys53
quaternary amine
– 2-arylpyridazin-3-one scaffold contributed
in cation-π interaction with Lys53Conclusion
We applied totally 60 ns MD simulations and ab initio
method to evaluate and compare the accuracy of these
methods in predicting pharmacophore models of three
different p38α MAPK inhibitors. Both methodologies
were able to unravel key interactions with different
p38α inhibitors. One advantageous feature of DFT-
based calculations is their relatively adaptable outputsregarding significantly shorter processing times due to
the incorporated approximations. Results indicated that
LJ interactions contributed significantly to binding of
SB203580, dihydroquinazolinone and 2-arylpyridazin-3-
one scaffolds despite the important role of electrostatic
interactions in initial approach of ligands to the receptor.
We used enzyme structure that was obtained by averaging
over last 10 ns of MD simulations for our ab initio studies.
This technique led to the results indicating that crystallo-
graphic primary structures may be used with care in such
calculations. Further investigations would be required to
rule out widespread structure activity relationships of
p38α inhibitory activity. Finally the results of the present
study may find their usefulness in pharmacophore based
modification of p38α inhibitors.
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